The objective of this study was to explore pretreatment factors predicting LVI status in patients undergoing NAC due to nonmetastatic luminal breast cancer who were ER +/HER2−, which are known to be associated with poorer response to chemotherapy as compared to other molecular subtypes. This evidence concerns the gene ERBB2 and breast cancer.